Aptamers are emerging as a unique class of therapeutics that hold significant promise to revolutionize healthcare. They are oligonucleotide or peptide molecules that bind to specific targets with high affinity and selectivity. Over the past few decades, aptamer technology has advanced tremendously, paving the way for their therapeutic applications. This article explores the potential of aptamers as novel drugs and highlights some of the ongoing research and clinical trials.
What are aptamers?
Aptamers are short, single-stranded DNA or RNA oligonucleotides ranging between 5-15 kDa in size that can specifically recognize and bind to molecular targets such as proteins, peptides, tissues, pathogens, toxins, and allergens. They are generated through an iterative selection process called Systematic Evolution of Ligands by EXponential enrichment (SELEX). SELEX involves repeatedly selecting aptamers from a random sequence library that can bind the target of interest with high affinity and specificity.
The selection process yields aptamers that fold into unique three-dimensional structures upon binding to their targets. This compact folding allows aptamers to bind to target molecules in highly specific sites and conformations, comparable to antibodies. However, aptamers offer advantages over antibodies such as easier and more cost-effective production through solid-phase chemical synthesis, longer shelf-life, non-immunogenicity, and easier modification.
Therapeutic applications
Due to their high target specificity and affinity, coupled with advantages over antibodies, aptamers are emerging as promising new therapeutics. A few potential therapeutic applications of aptamers include:
• Anticoagulation: NU172 and Regadenoson are aptamers that act as inhibitors of thrombin and platelet aggregation factor (PAF), respectively, and have entered clinical trials for anticoagulation.
• Anti-inflammatories: Mupadolimab acts against TNF-alpha to reduce inflammation and is being evaluated for treating rheumatoid arthritis. Other anti-TNF alpha and anti-IL-12 aptamers are also under development.
• Anticancer drugs: AS1411 targets nucleolin, which is overexpressed on tumor cells. It has completed Phase II trials for renal cell carcinoma and acute myeloid leukemia. Other targets include growth factors like vascular endothelial growth factor (VEGF).
• Anti-infectives: Certain aptamers bind to pathogens such as viruses, bacteria, and parasites and inhibit infection. For example, an anti-HIV aptamer is advancing through clinical trials. NOX-A12 targets C-X-C chemokine receptor type 4 to inhibit leukemia cell growth.
Aptamer-based diagnostics and biosensors
Besides therapeutics, aptamers are also impacting diagnostics and biosensing. Some key applications in these areas include:
- Disease diagnostics: Aptamers are developed against biomarkers for diseases and used to detect them in portable, easy-to-use test kits much like antibody-based tests. For example, aptamer-based kits exist for C-reactive protein detection.
- Food safety testing: Aptamer assays help detect contaminants, allergens, and pathogens in food. One example is a rapid test for aflatoxins - carcinogenic toxins produced by molds found in grains like corn.
- Environmental monitoring: Aptasensors using fluorescence, electrochemical signals help monitor environmental pollutants, heavy metals in water sources, etc.
- PoC testing: Small, handheld biosensors combine aptamers with microfluidics and electronics to enable point-of-care diagnostics outside labs. Applications range from glucose monitoring to infectious diseases.
While still in their relative infancy, aptamer-based solutions have significant potential to replace or augment traditional antibody-based techniques due to advantages like stability, synthetic production, and adaptability to portable platforms.
Challenges and future outlook
Despite rapid progress, some challenges remain for the development and commercialization of aptamer therapeutics and applications:
- Target specificity and stability in vivo: Further research is needed to evaluate the performance of aptamers inside complex biological systems and reduce off-target effects. Chemical modifications help but stability remains a hurdle.
- Upscaling and manufacturing: Larger scale preparation of aptamer libraries and optimized production methods will be required to meet potential commercial demands.
- Intellectual property: Complex patent landscapes for aptamers and SELEX technology exist, which requires navigation.
- Regulatory approval: Demonstrating safety, efficacy and production consistency for regulators is important for clinical translation.
However, the field is advancing rapidly through innovative research worldwide. In the coming years, we can expect to see many aptamer-based drugs approved and diagnostic/sensing kits commercialized. Their success could provide new options across therapeutic areas and enable more accessible testing. With potential applications almost limitless, aptamers appear poised to make a significant impact on medicine and healthcare.
Explore more information on this topic, Please visit-
https://www.insightprobing.com/aptamers-growth-and-trnds-analysis-share-size-demand-forecast/
Comments
0 comment